News

Odile Jaume to Lead Telix’s European Operations

Melbourne (Australia) and Brussels (Belgium) – 1st of March, 2018. Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), an clinical-stage biopharmaceutical company focused on...

Telix has established several EU/UK entities as part of delivering the Company’s intellectual property management, clinical operations and manufacturing activities in Europe. Telix is currently executing a significant portfolio of clinical research activities in Europe to support key clinical trials for TLX-250 and TLX-101, as well as indication expansion for Telix’s pipeline. Telix Co-Founder and CEO Dr. Christian Behrenbruch stated, “It’s my great pleasure to welcome Odile to the team, and for her to take charge of our European operations. Europe has a highly sophisticated nuclear medicine ecosystem that Odile knows very well, and we are pleased to have the benefit of her managerial and business development acumen.”

To read the full media release click here